Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) PT at $33.37

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given a consensus rating of “Moderate Buy” by the twenty brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $33.37.

A number of equities research analysts have recently weighed in on NTLA shares. Citigroup dropped their price objective on Intellia Therapeutics from $14.00 to $10.00 and set a “neutral” rating for the company in a research note on Friday, May 9th. Guggenheim lowered their target price on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating for the company in a report on Monday, May 12th. Wolfe Research raised Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price for the company in a research report on Monday, April 21st. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 16th. Finally, Chardan Capital reissued a “buy” rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a research note on Friday, May 9th.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $9.88 on Friday. The company’s 50 day simple moving average is $8.62 and its 200-day simple moving average is $9.41. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.18. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -1.89 and a beta of 2.21.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. Intellia Therapeutics had a negative net margin of 1,154.10% and a negative return on equity of 56.06%. The firm had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. During the same quarter last year, the firm earned ($1.12) EPS. The firm’s revenue for the quarter was down 42.6% on a year-over-year basis. Equities analysts expect that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently modified their holdings of the company. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth $43,177,000. Voloridge Investment Management LLC increased its holdings in Intellia Therapeutics by 226.8% in the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock valued at $17,805,000 after buying an additional 1,059,751 shares during the last quarter. Contrarius Group Holdings Ltd acquired a new stake in Intellia Therapeutics in the fourth quarter valued at $11,798,000. Two Sigma Advisers LP lifted its holdings in Intellia Therapeutics by 94.5% during the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock worth $23,300,000 after buying an additional 970,700 shares during the last quarter. Finally, Two Sigma Investments LP lifted its holdings in Intellia Therapeutics by 88.1% during the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock worth $21,498,000 after buying an additional 863,363 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.